Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma

Reynaert, H.; Rombouts, K.; Vandermonde, A.; Urbain, D.; Kumar, U.; Bioulac-Sage, P.; Pinzani, M.; Rosenbaum, J.; Geerts, A.
August 2004
Gut;Aug2004, Vol. 53 Issue 8, p1180
Academic Journal
Background: Somatostatin analogues have been used with conflicting results to treat advanced hepatocellular carcinoma (HCC}. The aim of this study was to investigate expression of somatostatin receptor (SSTR) subtypes in human liver, and to examine the effect of selective SSTR agonists on proliferation, apoptosis, and migration of hepatoma cells (HepG2, HuH7) and hepatic stellate cells (HSCs). Methods: Expression of SSTRs in cell lines, normal and cirrhotic liver, and HCC was examined by immunohistochemistry and reverse transcription-polymerase chain reaction. Effects of SSTR agonists on proliferation and apoptosis of tumour cells and HSCs were assessed by the 5-bromo-2' deoxyuridine and TUNEL methods, respectively. The influence of SSTR agonists on migration was investigated using Boyden chambers. Results: In normal liver, both hepatocytes and HSCs were negative for all five SSTRs. Cirrhotic liver and HCC as well as cultured hepatoma cells and HSCs expressed all five SSTRs, both at the protein and mRNA levels, except for HuH7 cells which did not immunoreact with SSTR3. None of the agonists influenced proliferation or apoptosis. However, compared with untreated cells, L-797,591, an SSTR1 agonist, reduced migration of HepG2, HuE-U, and HSCs significantly to 88 (7)% (p<0.05), 83 (1 1)% (p<0.05), and 67 (13)% (p<0.01), respectively. Conclusions: Cirrhotic liver and HCC express SSTRs. Although the somatostatin analogues used in this study did not affect proliferation and apoptosis, stimulation of SSTR1 may decrease invasiveness of HCC by reducing migration of hepatoma cells and/or HSCs. Clinical trials evaluating somatostatin analogues for the treatment of HCC should take these findings into account.


Related Articles

  • Critical appraisal of the role of everolimus in advanced neuroendocrine tumors of pancreatic origin. Mulet-Margalef, N�ria; Capdevila, Jaume // Gastrointestinal Cancer: Targets & Therapy;2012 Part 2, Vol. 2, p29 

    For many years, the treatment of advanced pancreatic neuroendocrine tumors (pNETs) has been limited almost entirely to somatostatin analogs and streptozocin-based chemotherapy, with modest benefit. Increasing knowledge of the biologic features of pNETs has allowed the design of molecular-based...

  • Review: Somatostatin and its analogues do not reduce mortality in acute bleeding esophageal varices. Korula, Jacob // ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p37 

    This article presents information on a study related to somatostatin, its analogues and whether it reduces mortality in acute bleeding esophageal varices. Randomized controlled trials compared somatostatin or its analogues with placebo or no treatment in patients with suspected or recently...

  • Management of Portal hypertension. Samonakis, D. N.; Triantos, C. K.; Thaiheimer, U.; Patch, D. W.; Burroughs, A. K. // Postgraduate Medical Journal;Nov2004, Vol. 80 Issue 949, p634 

    Treatment of portal hypertension is evolving based on randomised controlled trials. In acute variceal bleeding, prophylactic antibiotics are mandatory, reducing mortality as well as preventing infections. Terlipressin or somatostatin combined with endoscopic ligation or sclerotherapy is the best...

  • Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults. Nass, Ralf; Pezzoli, Suzan S.; Oliveri, Mary Clancy; Patrie, James T.; Harrell Jr., Frank E.; Clasey, Jody L.; Heymsfield, Steven B.; Bach, Mark A.; Vance, Mary Lee; Thorner, Michael O. // Annals of Internal Medicine;11/4/2008, Vol. 149 Issue 9, p601 

    Background: Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline of growth hormone in the development of sarcopenia is one of many factors, and its etiologic role needs to...

  • Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. Appetecchia, Marialuisa; Baldelli, Roberto // Journal of Experimental & Clinical Cancer Research (17569966);2010, Vol. 29, p19 

    Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are rare tumours that present many clinical features. They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. However, many are clinically silent until late presentation with mass...

  • Relevance of Hepatic Preneoplasia for Human Hepatocarcinogenesis. Qin Su; Bannasch, Peter // Toxicologic Pathology;Jan/Feb2003, Vol. 31 Issue 1, p126 

    Different lesions have been suggested to represent preneoplastic conditions in human liver. They include liver cell dysplasia, separated in large-cell change (LCC) and small-cell change (SCC), adenomatoid hyperplasia, and the more recently identified foci of altered hepatocytes (FAH) and nodules...

  • Somatostatin inhibits tooth-pulp-evoked rat cervical dorsal horn neuronal activity. Takahashi, M.; Takeda, M.; Matsumoto, S. // Experimental Brain Research;Feb2008, Vol. 184 Issue 4, p617 

    The aim of the present study is to investigate the effect of somatostatin (SST). It is well known that SST is a neuromodulator in the central nervous system and is involved in the regulation of metabolic and neuroendocrine functions. Recent experimental and clinical findings indicate a role for...

  • Lanreotide Autogel®: A Review of its Use in the Management of Acromegaly. Croxtall, Jamie D.; Scott, Lesley J. // Drugs;2008, Vol. 68 Issue 5, p711 

    Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of...

  • HEPATOPROTECTIVE ACTIVITY OF RHUS MYSORENSIS AGAINST CARBON TETRACHLORIDE INDUCED HEPATOTOXICITY IN ALBINO RATS. Gade, Deepak Reddy; Reddy G., Sree Kumar; Reddy Akki, Surya Narayana; Reddy P., Vamsi Rajasekhar // International Journal of Pharmaceutical Sciences Review & Resear;Sep2010, Vol. 4 Issue 3, p46 

    The whole plant of Rhus mysorensis of Anacardiaceae family is traditionally used in the treatment of diabetes. The aim of the present study was to evaluate the ethanolic extract of the whole plant of Rhus mysorensis for hepatoprotective effect against carbontetrachloride-induced liver damage in...


Read the Article


Sign out of this library

Other Topics